A detailed history of Pro Share Advisors LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 18,878 shares of RNA stock, worth $874,051. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,878
Previous 16,980 11.18%
Holding current value
$874,051
Previous $153,000 214.38%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$9.16 - $25.52 $17,385 - $48,436
1,898 Added 11.18%
18,878 $481,000
Q4 2023

Feb 14, 2024

BUY
$4.87 - $9.37 $14,385 - $27,678
2,954 Added 21.06%
16,980 $153,000
Q3 2023

Nov 13, 2023

BUY
$6.3 - $11.35 $1,568 - $2,826
249 Added 1.81%
14,026 $89,000
Q2 2023

Aug 10, 2023

BUY
$10.62 - $17.34 $12,574 - $20,530
1,184 Added 9.4%
13,777 $152,000
Q1 2023

May 11, 2023

BUY
$15.35 - $25.65 $18,466 - $30,856
1,203 Added 10.56%
12,593 $193,000
Q4 2022

Feb 02, 2023

BUY
$10.06 - $22.66 $13,661 - $30,772
1,358 Added 13.54%
11,390 $252,000
Q3 2022

Nov 04, 2022

BUY
$15.46 - $23.43 $155,094 - $235,049
10,032 New
10,032 $164,000
Q2 2022

Aug 01, 2022

SELL
$11.18 - $20.5 $133,198 - $244,237
-11,914 Closed
0 $0
Q1 2022

May 10, 2022

SELL
$14.2 - $23.78 $41,464 - $69,437
-2,920 Reduced 19.68%
11,914 $221,000
Q4 2021

Feb 08, 2022

BUY
$20.4 - $28.66 $5,140 - $7,222
252 Added 1.73%
14,834 $353,000
Q3 2021

Nov 12, 2021

SELL
$18.16 - $25.21 $526 - $731
-29 Reduced 0.2%
14,582 $359,000
Q2 2021

Aug 13, 2021

BUY
$19.62 - $29.26 $25,525 - $38,067
1,301 Added 9.77%
14,611 $361,000
Q1 2021

May 14, 2021

BUY
$20.28 - $28.15 $77,266 - $107,251
3,810 Added 40.11%
13,310 $290,000
Q4 2020

Feb 09, 2021

BUY
$24.73 - $35.12 $234,935 - $333,640
9,500 New
9,500 $242,000

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $2.41B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.